Indian Study Shows Merck's COVID-19 Antiviral Candidate Less Effective Against Moderate Infection: ReutersBenzinga • 10/08/21
Can This Duo Outperform Merck and Ridgeback Biotherapeutics' COVID Treatment?The Motley Fool • 10/08/21
Retail investors are dumping shares of COVID-19 vaccine makers and piling into antiviral pill maker Merck, data showsBusiness Insider • 10/06/21
ETFs to Play the Reopening Trade on Merck's Oral Antiviral Pill NewsZacks Investment Research • 10/04/21
Merck's Molnupiravir: If Peer Reviews Confirm Results, The Implications Would Be MassiveSeeking Alpha • 10/04/21